Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

Similar articles for PubMed (Select 21857161)

1.

Distinct requirements of hematopoietic stem cell activity and Nras G12D signaling in different cell types during leukemogenesis.

Wang J, Liu Y, Tan LX, Lo JC, Du J, Ryu MJ, Ranheim EA, Zhang J.

Cell Cycle. 2011 Sep 1;10(17):2836-9. Epub 2011 Sep 1.

2.

Oncogenic Kras initiates leukemia in hematopoietic stem cells.

Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS.

PLoS Biol. 2009 Mar 17;7(3):e59. doi: 10.1371/journal.pbio.1000059.

3.

Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.

Wang J, Liu Y, Li Z, Wang Z, Tan LX, Ryu MJ, Meline B, Du J, Young KH, Ranheim E, Chang Q, Zhang J.

Blood. 2011 Jul 14;118(2):368-79. doi: 10.1182/blood-2010-12-326058. Epub 2011 May 17.

4.

Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.

Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K.

Blood. 2011 Feb 10;117(6):2022-32. doi: 10.1182/blood-2010-04-280750. Epub 2010 Dec 16.

5.

Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.

Wang J, Kong G, Liu Y, Du J, Chang YI, Tey SR, Zhang X, Ranheim EA, Saba-El-Leil MK, Meloche S, Damnernsawad A, Zhang J, Zhang J.

Blood. 2013 Jun 27;121(26):5203-7. doi: 10.1182/blood-2012-12-475863. Epub 2013 May 17.

6.

Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.

Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA, Wang J, Zhang J.

J Biol Chem. 2013 Jun 21;288(25):18219-27. doi: 10.1074/jbc.M113.475376. Epub 2013 May 14. Erratum in: J Biol Chem. 2013 Dec 27;288(52):37368.

7.

Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.

Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF, Fleming MD.

Blood. 2009 Feb 5;113(6):1304-14. doi: 10.1182/blood-2008-01-134262. Epub 2008 Dec 9.

8.

Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.

Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, Shannon K, Morrison SJ.

Nature. 2013 Dec 5;504(7478):143-7. doi: 10.1038/nature12830. Epub 2013 Nov 27.

9.

Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.

Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K.

Cancer Discov. 2013 Sep;3(9):993-1001. doi: 10.1158/2159-8290.CD-13-0096. Epub 2013 Jun 3.

10.

A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells.

Xu D, Wang S, Yu WM, Chan G, Araki T, Bunting KD, Neel BG, Qu CK.

Blood. 2010 Nov 4;116(18):3611-21. doi: 10.1182/blood-2010-01-265652. Epub 2010 Jul 22.

11.

K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.

Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS.

Blood. 2007 May 1;109(9):3945-52. Epub 2006 Dec 27.

12.

Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals.

Du J, Liu Y, Meline B, Kong G, Tan LX, Lo JC, Wang J, Ranheim E, Zhang L, Chang YI, Ryu MJ, Zhang JF, Zhang J.

Leukemia. 2013 Mar;27(3):754-7. doi: 10.1038/leu.2012.251. Epub 2012 Aug 31. No abstract available.

13.

JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells.

Passegué E, Wagner EF, Weissman IL.

Cell. 2004 Oct 29;119(3):431-43.

PMID:
15507213
14.

Divergent effects of supraphysiologic Notch signals on leukemia stem cells and hematopoietic stem cells.

Chiang MY, Shestova O, Xu L, Aster JC, Pear WS.

Blood. 2013 Feb 7;121(6):905-17. doi: 10.1182/blood-2012-03-416503. Epub 2012 Oct 31.

15.

Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression.

Richter K, Pinto do O P, Hägglund AC, Wahlin A, Carlsson L.

Haematologica. 2003 Dec;88(12):1336-47.

16.

Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas.

Wolf S, Rudolph C, Morgan M, Büsche G, Salguero G, Stripecke R, Schlegelberger B, Baum C, Modlich U.

Oncogene. 2013 Jun 20;32(25):3028-38. doi: 10.1038/onc.2012.329. Epub 2012 Jul 30.

PMID:
22847614
17.

Pten loss in the bone marrow leads to G-CSF-mediated HSC mobilization.

Tesio M, Oser GM, Baccelli I, Blanco-Bose W, Wu H, Göthert JR, Kogan SC, Trumpp A.

J Exp Med. 2013 Oct 21;210(11):2337-49. doi: 10.1084/jem.20122768. Epub 2013 Oct 14.

18.

Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis.

Hartzell C, Ksionda O, Lemmens E, Coakley K, Yang M, Dail M, Harvey RC, Govern C, Bakker J, Lenstra TL, Ammon K, Boeter A, Winter SS, Loh M, Shannon K, Chakraborty AK, Wabl M, Roose JP.

Sci Signal. 2013 Mar 26;6(268):ra21. doi: 10.1126/scisignal.2003848.

19.

NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.

Xue L, Pulikkan JA, Valk PJ, Castilla LH.

Blood. 2014 Jul 17;124(3):426-36. doi: 10.1182/blood-2013-12-541730. Epub 2014 Jun 3.

PMID:
24894773
20.

Shp2 function in hematopoietic stem cell biology and leukemogenesis.

Nabinger SC, Chan RJ.

Curr Opin Hematol. 2012 Jul;19(4):273-9. doi: 10.1097/MOH.0b013e328353c6bf. Review.

PMID:
22504523
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk